EWTX 주식 개요 에지와이즈 테라퓨틱스는 바이오 제약 회사로 근육 질환 치료를 위한 치료법을 발견, 개발, 상용화하는 기업입니다. 자세한 내용
{"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
생각, 링크 및 회사 내러티브를 캡처하세요.
Edgewise Therapeutics, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Edgewise Therapeutics 과거 주가 현재 주가 US$26.16 52주 최고치 US$38.12 52주 최저치 US$14.90 베타 0.21 1개월 변경 8.32% 3개월 변경 사항 -21.35% 1년 변경 사항 38.34% 3년 변화 99.24% 5년 변화 n/a IPO 이후 변화 -12.80%
최근 뉴스 및 업데이트
Chief Medical Officer exercised options and sold US$514k worth of stock Feb 02
Edgewise Therapeutics, Inc. Announces Executive Changes Jan 22
New major risk - Shareholder dilution Jan 16
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data Dec 31
Chief Development Officer exercised options and sold US$616k worth of stock Dec 29
Price target increased by 10% to US$47.57 Dec 16 더 많은 업데이트 보기
Chief Medical Officer exercised options and sold US$514k worth of stock Feb 02
Edgewise Therapeutics, Inc. Announces Executive Changes Jan 22
New major risk - Shareholder dilution Jan 16
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data Dec 31
Chief Development Officer exercised options and sold US$616k worth of stock Dec 29
Price target increased by 10% to US$47.57 Dec 16
Edgewise Therapeutics, Inc. Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy Dec 16
Price target increased by 11% to US$45.86 Nov 27
Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation Nov 26
New major risk - Revenue and earnings growth Nov 22
Edgewise Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 05
General Counsel exercised options and sold US$1.9m worth of stock Sep 30
Chief Financial Officer recently sold US$830k worth of stock Sep 26
Chief Financial Officer notifies of intention to sell stock Sep 23
New major risk - Share price stability Sep 20
Price target increased by 11% to US$36.67 Sep 19
Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade) Sep 19
Edgewise Therapeutics, Inc Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) Sep 19
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth Aug 12
Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal Aug 05
Edgewise Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 04
New major risk - Revenue and earnings growth May 13 Edgewise Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million. May 11
High number of new directors May 10
Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run May 10
We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate May 10
Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors May 08 Edgewise Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024
Edgewise Therapeutics, Inc., Annual General Meeting, Jun 07, 2024 Apr 28
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) Apr 16
Price target increased by 16% to US$30.50 Mar 08
Edgewise Therapeutics: Behind The Massive Rally Feb 18
Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) Feb 14
General Counsel notifies of intention to sell stock Feb 10
Chief Financial Officer notifies of intention to sell stock Jan 25
New minor risk - Shareholder dilution Jan 19 Edgewise Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $240.000002 million. Jan 19
General Counsel notifies of intention to sell stock Jan 05
Co-Founder recently sold US$1.6m worth of stock Dec 30
Co-Founder notifies of intention to sell stock Dec 29
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth Dec 07
Edgewise Therapeutics, Inc. Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA Dec 01
New major risk - Revenue and earnings growth Nov 10
Edgewise Therapeutics Announces Expansion of Their Edg-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne) Oct 27
Edgewise Therapeutics, Inc. Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker) Sep 27
Edgewise Therapeutics, Inc. Begins Dosing First-In-Human Phase 1 Trial of EDG-7500 Sep 15
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans Aug 16
Price target increased by 17% to US$27.40 Jun 30
Edgewise Therapeutics, Inc. Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) Jun 27
New minor risk - Share price stability Jun 19
Price target increased by 15% to US$27.40 May 13
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth Apr 28
Price target increased by 19% to US$28.75 Feb 24
We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth Jan 13
Edgewise Therapeutics, Inc. Appoints Marc Semigran as Chief Development Officer Dec 21
Edgewise Therapeutics Announces Initiation of Lynx Phase 2 Clinical Trial of Edg-5506 for the Treatment of Duchenne Muscular Dystrophy Oct 28
Edgewise Therapeutics, Inc. Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy Oct 14
Edgewise Therapeutics proposes $100M stock offering plan Sep 13
Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) Sep 12
General Counsel notifies of intention to sell stock Sep 10
Edgewise Therapeutics, Inc. Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy Sep 08
General Counsel exercised options and sold US$74k worth of stock Aug 06
Price target increased to US$30.00 Aug 05
Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02 Aug 04
Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth Aug 02
Edgewise Therapeutics Now Enrolling Canyon Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) Jul 13
General Counsel exercised options and sold US$65k worth of stock Jul 09 Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2000 Growth Index Edgewise Therapeutics Inc. Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Jun 21
General Counsel exercised options and sold US$226k worth of stock Jun 08
Price target decreased to US$25.60 May 23
General Counsel notifies of intention to sell stock May 20
Price target increased to US$31.00 May 12
Edgewise Therapeutics, Inc. Anticipates Initiation of Phase 2 Trials in Individuals with BMD (NCT05291091) in the Second Quarter of 2022 and BMD in the Second Half of 2022 May 12
High number of new directors Apr 27
Edgewise Therapeutics, Inc. Announces the Initiation of an Edgewise-Funded Observational Trial in Individuals with BMD Apr 15
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely Mar 24
Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD) Jan 06
High number of new directors Jan 01
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study Dec 16
We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely Nov 23
Co-Founder recently sold US$781k worth of stock Nov 05
Co-Founder recently sold US$672k worth of stock Sep 28
Co-Founder notifies of intention to sell stock Sep 28
Edgewise Therapeutics, Inc. Announces Publication of Data Demonstrating the Elevation of Fast But Not Slow Skeletal Muscle Fiber Injury Biomarkers in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy May 05
Edgewise Therapeutics names new chief medical officer Apr 27 주주 수익률 EWTX US Pharmaceuticals US 마켓 7D -11.3% 1.2% 0.2% 1Y 38.3% 1.4% 23.1%
전체 주주 수익률 보기
수익률 대 산업: EWTX 지난 1년 동안 1.4 %를 반환한 US Pharmaceuticals 산업을 초과했습니다.
수익률 대 시장: EWTX 지난 1년 동안 23.1 %를 반환한 US 시장을 초과했습니다.
가격 변동성 Is EWTX's price volatile compared to industry and market? EWTX volatility EWTX Average Weekly Movement 9.2% Pharmaceuticals Industry Average Movement 10.1% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.3% 10% least volatile stocks in US Market 3.0%
안정적인 주가: EWTX 지난 3개월 동안 US 시장에 비해 상당한 가격 변동성이 발생하지 않았습니다.
시간에 따른 변동성: EWTX 의 주간 변동성 ( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 에지와이즈 테라퓨틱스는 바이오 제약 회사로 근육 질환 치료를 위한 치료법을 발견, 개발 및 상업화합니다. 주요 제품 후보인 EDG-5506은 듀센 근이영양증과 베커 근이영양증을 포함한 근이영양증의 근본 원인을 해결하기 위해 설계된 경구용 저분자 약물로 임상 2상 시험 중입니다. 이 회사는 비후성 심근증 및 기타 중증 심장 질환 치료를 위한 저분자 약물인 EDG-7500을 개발하여 임상 1상 시험을 진행 중입니다.
자세히 보기 Edgewise Therapeutics, Inc. 기본 사항 요약 Edgewise Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요? EWTX 기본 통계 시가총액 US$2.49b 수익(TTM ) -US$124.29m 수익(TTM ) n/a
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) EWTX 손익 계산서(TTM ) 수익 US$0 수익 비용 US$0 총 이익 US$0 기타 비용 US$124.29m 수익 -US$124.29m
주당 순이익(EPS) -1.31 총 마진 0.00% 순이익 마진 0.00% 부채/자본 비율 0%
EWTX 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/11 13:56 장 마감 주가 2025/02/11 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기 .
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.
애널리스트 출처 Edgewise Therapeutics, Inc. 10 애널리스트 중 7 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Cory Kasimov Evercore ISI Madhu Kumar Goldman Sachs Paul Choi Goldman Sachs
7 더 많은 분석가 보기 
